The latest price target for Sonoma Pharmaceuticals (NASDAQ:SNOA) was reported by Ladenburg Thalmann on September 5, 2023. The analyst firm set a price target for $3.25 expecting SNOA to rise to within 12 months (a possible 24.32% upside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Sonoma Pharmaceuticals (NASDAQ:SNOA) was provided by Ladenburg Thalmann, and Sonoma Pharmaceuticals initiated their buy rating.

There is no last upgrade for Sonoma Pharmaceuticals

There is no last downgrade for Sonoma Pharmaceuticals.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sonoma Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sonoma Pharmaceuticals was filed on September 5, 2023 so you should expect the next rating to be made available sometime around September 5, 2024.

While ratings are subjective and will change, the latest Sonoma Pharmaceuticals (SNOA) rating was a initiated with a price target of $0.00 to $3.25. The current price Sonoma Pharmaceuticals (SNOA) is trading at is $2.61, which is within the analyst’s predicted range.